Table 2. GWAS covariate determination: linear regression analyses for total morphine sulfate dose requirement in children of European Caucasian and African-American ancestry.
| EC (n=293) | AA (n=251) | ||||
|---|---|---|---|---|---|
| Beta | P-value | Beta | P-value | ||
| Age | -0.115 | 3.23×10-2 | -0.209 | 8.24×10−4 | |
| Sex | +3.99 | 0.407 | -3.10 | 0.541 | |
| BMI | -2.52 | 2.80×10-6 | -2.23 | 3.84×10-9 | |
| ASA PS | -11.59 | 2.36×10-2 | -14.54 | 1.65×10-2 | |
| Oxycodone* | -1.30x10-3 | 0.977 | +7.10×10-2 | 0.156 | |
Analyses included all those subjects for whom full phenotype information was available.
*
Oxycodone refers to oral opioid administration time after postanesthesia recovery room admission. AA=African-American, ASA PS = American Society of Anesthesiologists' physical status, Beta = regression coefficient, BMI=body mass index, EC=European Caucasian ancestry, GWAS = genome-wide association study.